Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Abatacept Injection Clear all
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 6, 2026, 2:02 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 6, 2026, 2:02 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

NCT03882008
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

The Study of Abatacept in Combination With Etanercept

NCT00162279
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
35
States / cities
Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2010 · Synced Sep 6, 2026, 2:02 PM EDT
Terminated Phase 1 Interventional

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

NCT04203875
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
Orencia® (Abatacept)
Drug
Lead sponsor
Stuart Knechtle, M.D.
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2021 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

NCT01142726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 6, 2026, 2:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 6, 2026, 2:02 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of COYA 302 for the Treatment of ALS

NCT07161999
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
44
States / cities
Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

Study on the Safety of Abatacept in Relapsing Polychondritis

NCT01272856
View directory record Official record
Conditions
Relapsing Polychondritis
Interventions
Abatacept
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

NCT03841357
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Abatacept Injection, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 16 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

NCT00119678
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 6, 2026, 2:02 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route

NCT06126042
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Test Product, Reference product, Reference Medicinal Product
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Biological
Lead sponsor
Arthritis & Rheumatic Disease Specialties Research
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 6, 2026, 2:02 PM EDT
Terminated Early Phase 1 Interventional

Trial of Orencia in Patients With Myasthenia Gravis

NCT03059888
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Abatacept Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

NCT01860976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 4 Interventional Results available

Abatacept in Juvenile Dermatomyositis

NCT02594735
View directory record Official record
Conditions
Dermatomyositis
Interventions
Abatacept
Drug
Lead sponsor
George Washington University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

NCT02161406
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Abatacept Versus Adalimumab Head-to-Head

NCT00929864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
63
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 6, 2026, 2:02 PM EDT
Completed Phase 1Phase 2 Interventional

Novel Desensitization Kidney Transplantation

NCT05345717
View directory record Official record
Conditions
Kidney Transplantation, End Stage Kidney Disease (ESRD)
Interventions
Belatacept Injection
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 6, 2026, 2:02 PM EDT